Scope & Claims Analysis and U.S. Patent Landscape for Drug Patent 8,590,530 (Nasal delivery device using exhaled air, temperature regulation, and container chamber controls)

Executive summary

U.S. Patent 8,590,530 claims a nasal insufflation delivery system that uses a mouthpiece through which the subject exhales to drive airflow through an inlet/outlet container chamber and then out through a nosepiece. The independent claim centers on an air chamber fluidly connecting the mouthpiece to the inlet that incorporates a temperature regulator to regulate (including cool) the exhaled-air temperature, with dependent claims narrowing the air chamber-to-container chamber volume ratio, temperature regulator placement and extent, and pressure-sensitive valve behavior. The claim set also covers multiple mechanical variants for container mounting, rotatability under airflow, replaceability/reuse, and a capsule combination.

From a patent-enforcement and freedom-to-operate perspective, claim coverage clusters into three technical “attack surfaces”:

Exhalation-driven airflow + temperature-regulated air chamber upstream of the container chamber to manage condensation.
Container chamber architecture and flow control (volume relationships, pressure-sensitive valve, inlet aperture/seat, partial fill opening mechanisms).
Container forms and integration (replaceable container-containing member, rotatable container within a flow passage, capsule combination).

The estate is likely to block or price-in licensing for competitors pursuing device-level nasal powder delivery driven by patient exhalation and temperature-conditioned exhaled air. Design-arounds that eliminate the temperature regulator in the air chamber or replace the exhalation-driven mechanism with a non-exhalation actuator (e.g., compressor/propellant) are the most direct claim-avoidance paths.

What does U.S. Patent 8,590,530 claim for nasal delivery devices driven by patient exhalation?

Answer: A nasal delivery device using exhaled air to entrain powder (or substance) from a container chamber and deliver it through a nasal nosepiece, with an air chamber that includes a temperature regulator to cool/regulate the exhaled airflow.

Independent claim 1 core elements (device)

Claim 1 is a structural-functional combination with these required components:

Container-receiving unit
- Container chamber with inlet and outlet.
- Receives a substance-containing container holding the substance to be delivered intranasally.
Nosepiece unit
- Nosepiece fitted to a nasal cavity.
- Fluid communication with the container chamber outlet.
Mouthpiece unit
- Mouthpiece through which the subject exhales in use.
- Fluid communication with the container chamber inlet.
Air chamber
- Fluidly connects mouthpiece to the container-chamber inlet.
- Incorporates a temperature regulator for regulating the temperature of the air flow as exhaled through it.

Dependent claim 2-6 volume/placement/extent refinements

Claim 2: air chamber volume > container chamber volume.
Claim 3: air chamber volume at least 2x container chamber volume.
Claim 4: temperature regulator is configured to cool exhaled air flow.
Claim 5: temperature regulator is located at least at the upstream end of the air chamber.
Claim 6: temperature regulator substantially fills the air chamber.

Practical implication: these claims favor designs where the temperature-conditioning happens in a relatively large upstream air path and with a meaningful thermal mass/geometry (substantially filling).

Dependent claim 7-9 flow-pressure and removability

Claim 7: pressure-sensitive valve in fluid communication with the container-chamber inlet that stays open only after a predetermined upstream pressure develops.
Claim 8: pressure-sensitive valve is included in the container-receiving unit.
Claim 9: nosepiece unit is removable.

This is a gating mechanism claim: a competitor that uses a pressure-dampening element may still infringe if it functions like a pressure-sensitive valve that closes until a threshold is reached.

Claim 10 capsule combination

Claim 10: combination of the device of claim 1 with a capsule containing a powdered substance.

This ties device coverage to a specific container form factor that matters for product packaging and downstream infringement theories.

What additional architecture is claimed in independent claim 11 (rotatable container-containing member)?

Answer: A second major device family where the container sits in a rotatable flow passage inside a container-containing member, driven by exhaled airflow, with temperature regulation and optional pressure-sensitive valve.

Independent claim 11 requires:

Container-receiving unit with:
- container chamber inlet/outlet.
- a container-containing member that includes a flow passage in which the container is rotatable when an air flow is delivered therethrough.
Nosepiece unit
- nosepiece in fluid communication with outlet.
Mouthpiece unit
- mouthpiece in fluid communication with inlet, through which the subject exhales to entrain substance and deliver through nosepiece.

Dependent claim 12-14: air chamber and temperature regulator

Claim 12: mouthpiece unit further comprises an air chamber connecting mouthpiece to inlet.
Claim 13: air chamber volume > container chamber.
Claim 14: air chamber incorporates temperature regulator.

Notably, claim 11 itself doesn’t repeat the explicit exhaled-air temperature regulation in the independent clause; dependent claim 14 makes it an asserted limitation when pursued under the dependent claim set.

Dependent claim 15-16: pressure-sensitive valve

Claim 15: pressure-sensitive valve closes inlet until predetermined upstream pressure.
Claim 16: valve is within container-receiving unit.

Dependent claim 17-23: removability, replaceability, reuse

Claim 17: nosepiece unit removable.
Claim 18: nosepiece unit includes container-containing member; the container-containing member is fitted in the container chamber when fitting the nosepiece unit.
Claims 21-22:
- replaceable container-containing member containing the container.
- container-containing member replaceable separately from nosepiece; nosepiece reusable.
Claim 23:
- container replaceable.
- nosepiece and container-containing member reusable.

Dependent claim 19-20: inlet aperture and container seat (flow restriction geometry)

Claim 19: container-containing member includes inlet aperture in fluid communication with one upstream end of the flow passage providing a flow restriction.
Claim 20: inlet aperture provides a seat on which a lower end of the container is seated before air delivery.

Dependent claim 24-25: container opening mechanism (dual piercing elements; partial fill)

Claim 24: container-opening mechanism operative to open a container as received in chamber.
Claim 25:
- container only partially filled.
- opening mechanism includes first and second piercing elements.
- one pierces at a height above the fill level; the other pierces an upper region.

This is a specific mechanical dosing-flow improvement claim.

Dependent claim 26: capsule combination

Claim 26: combination of claim 11 device with a capsule containing powdered substance.

Independent claim 27 and 28: method coverage (condensation control explicitly appears in claim 27)

Claim 27 method explicitly recites:

exhaling through mouthpiece and air chamber including temperature regulator.
delivering airflow through container chamber to entrain substance and deliver to nasal cavity.
drawing moisture from exhaled air upstream of the container chamber to reduce condensation at or downstream of container chamber.
regulating a temperature of exhaled air through the temperature regulator.

Claim 28 method emphasizes:

exhaling through mouthpiece in communication with inlet to deliver airflow through container chamber.
rotate the container within flow passage of container-containing member.
entrain substance and deliver through nosepiece.

Practical implication: claim 27 gives a direct “condensation reduction” functional limitation that can strengthen infringement posture for device embodiments that use cooling/conditioning to reduce moisture deposition.

Where are the key claim limitations likely to be litigated?

Answer: Temperature regulation in the air chamber, the exhalation-driven mechanism, airflow path definitions (air chamber connecting mouthpiece to container inlet), and the pressure-sensitive valve thresholds.

“Temperature regulator” scope: device structure + cooling intent

Claims repeatedly require a “temperature regulator” in the air chamber regulating the temperature of air as exhaled therethrough, with dependent claims specifically calling out cooling and upstream location. Competitors will fight over whether their thermal module:

sits “at least at an upstream end,”
“substantially fills” the air chamber, and
actually regulates exhaled-air temperature “through the air chamber” versus conditioning elsewhere.

Air chamber volume relationships

Claims 2-3 and 13 create quantitative-ish constraints:

air chamber volume greater than container chamber;
at least twice, for claim 3. These are high leverage for both infringement and invalidity arguments where measurement/architecture can be compared.

Pressure-sensitive valve threshold behavior

Claim 7 and claim 15 are functional but specific:

configured to close the inlet until a predetermined pressure develops upstream. Any alternative that uses a spring valve, elastomer valve, or flow restrictor without a pressure-triggered closure could avoid.

Rotatable container-containing member claims (claim 11 family)

Claim 11’s container rotatability “when an air flow is delivered therethrough” is a distinct design pillar. Designs that keep the capsule static but use airflow shear or vibration may fall outside this limitation.

Partial-fill double piercing (claim 25)

This is a narrow mechanical refinement. It is unlikely to be used unless a competitor’s capsule-handling scheme matches the partial-fill and dual piercing geometry.

What is the patent landscape around this concept for nasal powder delivery with exhaled air and thermal conditioning?

Answer: The landscape divides into (i) patient-actuated intranasal powder delivery devices, (ii) moisture/condensation control using temperature conditioning, and (iii) capsule/container handling mechanisms that control airflow and opening.

Because only U.S. Patent 8,590,530 text and claims are provided here, this analysis is limited to claim-anchored landscape mapping rather than listing every related patent number. Under that constraint, the patent landscape logically clusters into these adjacent technology bins:

1) Patient exhalation-driven aerosolization/insufflation

Patents in this bin cover mouthpiece + nasal interface systems where patient breathing provides motive airflow, often combined with:

flow restriction,
valve gating,
powder entrainment into airflow,
capsule or reservoir integration.

2) Thermal conditioning of breathing air to mitigate condensation/deposition

Patents here focus on:

cooling exhaled air,
dehumidifying/drying exhaled air,
thermal management upstream of a powder container to avoid caking or moisture deposition. Claim 27’s explicit “drawing moisture upstream” provides a direct bridge to this bin.

3) Container chamber architectures and capsule opening

Sub-bins include:

piercing systems for capsules,
partial fill handling,
replaceable cartridge or nosepiece modules,
flow passages that move, rotate, or otherwise agitate contents.

4) Rotational capsule/container mechanisms

A narrower bin: container rotation in a flow passage. Claim 11’s rotatability requirement is a strong distinguishing limitation.

How strong is the patent estate for U.S. Patent 8,590,530 (claim breadth vs. narrow dependents)?

Answer: Broadest protection is in the independent claim 1 device architecture with temperature-regulated exhaled air in the air chamber, plus independent claim 11’s rotatable container-flow passage variant. Multiple dependent claims add specific quantitative and mechanical limitations.

Claim 1 is the breadth anchor

Claim 1 covers any nasal delivery device meeting all its structural components, with temperature regulation being the central limiting feature. Even if a competitor avoids capsule form (claim 10), the device claims still capture.

Claim 11 is the alternative breadth anchor

Claim 11 introduces a second independent architecture with rotatable container-containing member. Competitors choosing rotational mechanics will face a higher infringement risk.

Dependent claims create “layered” enforcement options

Volume ratio (2x) and “substantially fills” provide tighter routes in suits.
Pressure-sensitive valve and removable nosepiece add narrower but still enforceable variants.
Capsule combination claims help for product-market mapping (if the commercial unit uses capsules).

Practical enforceability note

If competitors use exhalation-driven nasal delivery but implement temperature regulation outside the “air chamber” (as claimed), or omit cooling of exhaled air, their exposure shifts dramatically. The temperature regulator location and function are likely the principal battleground.

When does U.S. Patent 8,590,530 lose exclusivity? (Expiration and regulatory exclusivity)

Answer: Not determinable from the provided information.

A complete exclusivity and patent-expiration timeline requires at least one of: application/filing dates, patent issue date confirmation, priority dates, or related FDA product linkage (Orange Book entry with listed patents). None is included in the prompt.

What Orange Book status would this patent likely have for marketed intranasal powders?

Answer: Not determinable from the provided information.

Orange Book status depends on the specific drug product to which 8,590,530 is listed, which is not provided.

What patent litigation risks exist for companies developing competing intranasal devices?

Answer: Litigation exposure is highest for designs that copy the exhalation-driven pneumatic path combined with a temperature-regulated air chamber and the defined container chamber inlet/outlet architecture.

Key risk profiles:

Exhalation-driven nasal insufflation + upstream cooling/dehumidifying air chamber
- Strongest alignment with claim 1 and method claim 27.
Same but without the pressure-sensitive valve
- May avoid claims 7/15 if the valve is essential to the asserted dependent claim set. Independent claim coverage may remain depending on design.
Rotatable container in a flow passage
- Strong alignment with claim 11 and method claim 28.
Replaceable container-containing member/nosepiece reuse
- Alignment with claims 17-23.

How does U.S. Patent 8,590,530 compare with likely competitor design choices?

Answer: Exposure maps to whether competitors adopt the claimed thermal-conditioning and container-fluid-communication architecture.

Design choice comparison matrix (claim-to-design)

Competitor design element	Matches claim language?	Likely coverage impact
Patient exhales through mouthpiece; exhaled airflow drives entrainment	Claim 1/11/27/28	Core match
Air chamber fluidly connects mouthpiece to container chamber inlet	Claim 1/27	Core match
Temperature regulator in air chamber; regulates temperature of exhaled air	Claim 1/27	Core match; major infringement hinge
Cooling of exhaled air	Claim 4/27	Strengthens claim alignment
Temperature regulator at upstream end; substantially fills	Claim 5/6	Narrows to high-specificity embodiments
Pressure-sensitive valve closes inlet until threshold	Claim 7/15	Adds dependent claim risk; absence may avoid those dependents
Container chamber inlet aperture provides flow restriction and seat	Claim 19-20	Dependent alignment only
Container opening uses dual piercing for partial fill	Claim 25	Dependent, mechanical match only
Container rotates within flow passage under airflow	Claim 11/28	Independent 11 family alignment

What generic entry risks exist for the device and capsule combination?

Answer: Risk is primarily product-form and device-function driven, not classic “generic drug” risk.

Because claim 10 and 26 are capsule combinations and the device is a system claim, a “generic entry” would look like:

new capsule form compatible with the device,
or a device redesign that avoids the temperature-regulation limitation.

The system-level claims mean that even if a capsule is different, infringement can still attach if the device system is within the claim scope. Conversely, if a competitor uses a different thermal-conditioning scheme, it may clear system claims even when using similar capsules.

Key Takeaways

U.S. Patent 8,590,530 covers nasal powder/substance delivery driven by patient exhalation, using a mouthpiece-air chamber-container chamber-nosepiece fluid path.
The patent’s defining limitation is an air chamber incorporating a temperature regulator that regulates the temperature of exhaled air, with multiple dependent claims specifying cooling, upstream placement, and substantially filling the air chamber.
The claim set also protects mechanical variants: pressure-sensitive valve threshold gating, replaceable modules, rotatable container-containing members, and container opening mechanisms (including a dual piercing approach for partial fill).
Method claims expand coverage with condensation/moisture reduction upstream of the container chamber via temperature regulation.
The highest infringement risk is for competing intranasal devices that preserve the exhalation-driven mechanism and the temperature-regulated air chamber feature as claimed; the lowest risk is for designs that eliminate or relocate that thermal function or switch to non-exhalation actuation.

FAQs

1) What is the single most important limitation to avoid when designing around U.S. Patent 8,590,530?
The temperature regulator in the air chamber that regulates the temperature of air as exhaled through that air chamber.

2) Do the capsule claims create standalone infringement for capsule suppliers?
No standalone position is stated in the provided text; claims are “combination” claims paired with the device.

3) Does the patent require cooling or is temperature regulation alone sufficient?
Claim 1 requires “temperature regulator” broadly; dependent claim 4 expressly requires cooling.

4) Can a competitor infringe even if it removes the pressure-sensitive valve?
If an asserted claim does not require the pressure-sensitive valve (independent claims), yes. Pressure valve risk is mainly tied to dependent claims 7 and 15.

5) What differentiates independent claim 11 from claim 1?
Independent claim 11 adds a container-containing member with a flow passage where the container is rotatable when air flows through.

References

None provided in the prompt for citation.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005283922	⤷ Start Trial
Brazil	PI0515289	⤷ Start Trial
Canada	2580217	⤷ Start Trial
Canada	2839080	⤷ Start Trial
Canada	2904711	⤷ Start Trial
China	101056666	⤷ Start Trial
China	102000374	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,590,530